A new version is available
FDA approval of Casgevy (the first CRISPR-based therapy) and Lyfgenia for sickle cell disease.
Source
Cited 1 time
FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease
U.S. Food and Drug Administration · December 2023